This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Commissariat a L'energie Atomique Et Aux Energies Alternatives. Active years: 2020.
Company Filing History:
Years Active: 2020
Title: Claire Chevaleyre: Innovator in Cancer Immunotherapy
Introduction
Claire Chevaleyre is a prominent inventor based in Paris, France. She has made significant contributions to the field of cancer immunotherapy through her innovative research and development of immunogenic peptides.
Latest Patents
Claire Chevaleyre holds a patent for "Immunogenic peptides of the cyclin B1 tumor antigen." This invention relates to peptides that comprise at least one CD4T epitope, which is immunodominant in vitro. These peptides are capable of stimulating a specific human CD4T lymphocyte response in subjects with varied HLA II molecules. The peptides are intended for use as a cancer vaccine and as a reagent for the diagnosis of cancer or for immunomonitoring the cellular response against cyclin B1 during cancer or anticancer treatment. She has 1 patent to her name.
Career Highlights
Claire Chevaleyre is affiliated with the Commissariat à l'énergie atomique et aux énergies alternatives, where she continues her research in cancer immunotherapy. Her work has been instrumental in advancing the understanding of tumor antigens and their role in cancer treatment.
Collaborations
Throughout her career, Claire has collaborated with notable colleagues, including Bernard Maillere and Florence Castelli-Golfier. These collaborations have enriched her research and contributed to the development of innovative solutions in cancer treatment.
Conclusion
Claire Chevaleyre is a trailblazer in the field of cancer immunotherapy, with her groundbreaking patent and collaborative efforts paving the way for future advancements in cancer treatment. Her work exemplifies the impact of innovation in addressing critical health challenges.